Dr Jonathan Gee

Investment Director and Chairman of North West Fund for Biomedical Investment Committee
 
 

Biography

Jonathan is chairman of the investment committee of Spark Impact.  His background is healthcare and life sciences investments. He has nearly twenty years experience supporting IP driven high growth technology companies as an investor, board member and as Chief Executive of technology exploitation companies. His investment focus covers all healthcare from drug discovery to devices and diagnostics.

Investments he led include Oxford Immunotec Global plc, which is in the process of being acquired at a valuation of over $500m by Perkin Elmer, Immunocore, a privately held late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune, Oxitec, a manufacturer of GM insects for control of dengue fever, zika virus and chikungunya, acquired by NYSE quoted Intrexon Corp for over £100m in 2015, Natural Motion, a mobile gaming company acquired by Zynga Inc for over $500m in 2014, and GlycArt Biotechnology, acquired by Roche for over £100m in July 2005.

Jonathan formerly managed the Isis College Funds for Oxford University and a number of its Colleges.  Prior to joining SPARK, he was involved for over ten years in the identification and development of intellectual property as the basis for innovative new products, arising from University research.  As Chief Executive of Imperial College Innovations, he was responsible for spinning out over 30 new University start up companies.

He established the first seed fund at Imperial College and ran this for its first two years. He has a background in marketing in the medical diagnostics industry where he was International Product Group Manager for Unilever’s successful OTC testing lateral flow technology company, Unipath. He gained his management training in Unilever, which he joined following a PhD in cancer research at Oxford University.